Pharmacokinetics– tag –
-
Lonza to Build New Spray-Drying Facility in Oregon, US, Bolstering CDMO Capabilities in Particle Engineering for Enhanced Bioavailability
SWI swissinfo.ch Switzerland Overview Lonza, a leading Swiss CDMO, announced on September 10, 2026, plans to construct a new state-of-the-art manufacturing facility in Bend, Oregon, specialized in spray-drying technology. Expected to be ... -
Rani Therapeutics Achieves 84% Bioavailability for Oral Ustekinumab Biosimilar; Oral GLP-1s Drive Commercial Success in Biopharma Delivery
Drug Delivery Leader USA Overview The successful FDA approval and commercial launch of oral semaglutide (Wegovy) and orforglipron highlight the critical role of oral delivery in chronic disease management, significantly improving patient... -
Nutshell Therapeutics’ NRF2 Molecular Glue Degrader NTS231 Clears FDA IND, Becomes China’s First and World’s Second to Enter Clinical Development
Insight, China's Pharmaceutical Industry China Overview Nutshell Therapeutics' NRF2 molecular glue degrader, NTS231, has cleared FDA IND, becoming the first from China and second globally to enter clinical development as a novel therapeu... -
Antibody-Drug Conjugates Prepared with Peptide Asparaginyl Ligase Enhance Uniformity and Antitumor Activity, Promising Pharmaceutical Applications
Molecular Cancer Therapeutics (AACR Journals) USA Overview Novel antibody-drug conjugates (ADCs) prepared using peptide asparaginyl ligase (PAL) demonstrated potent antitumor activity in both in vitro and in vivo models. This innovative ... -
Pin Therapeutics Unveils Oral CK1α Molecular Glue Degrader PIN-5018 for Adenoid Cystic Carcinoma at China TPD Forum, Phase 1 Underway Targeting FDA Accelerated Approval
Korea Biomedical Review South Korea Overview Pin Therapeutics presented PIN-5018, an oral CK1α-selective molecular glue degrader for adenoid cystic carcinoma (ACC), derived from its proprietary PinMARS platform, at the China Targeted Pro... -
Oral Absorption of Therapeutic Peptides Remains Below 1%, MDPI Review Identifies Enzymatic Degradation, pH, Microbiota as Key Barriers
MDPI Unknown Overview A new MDPI review provides a comprehensive analysis of the complex physiological determinants influencing the oral absorption of therapeutic peptides. It confirms that the bioavailability of oral peptides typically ... -
Nanotechnology Overcomes Drug Delivery Challenges: Liposomes & Polymeric Nanoparticles Enhance Drug Solubility and Targeted Delivery
Scientific Review Unknown Overview A recent review highlights nanotechnology's transformative role in overcoming traditional drug delivery challenges, such as poor solubility and non-specific distribution. Diverse nanocarriers, including... -
Lonza Capsugel Pioneers Dual-Layer Strategy for Oral GLP-1 Delivery, Shielding Peptides from Enzymatic Attack
Capsugel (Lonza) Switzerland Overview Lonza Capsugel has engineered a novel dual-layer protection strategy to enable oral delivery of GLP-1 peptides, circumventing the critical challenge of enzymatic degradation within the gastrointestin... -
Organ-on-Chip Platforms Accelerate Nanoparticle DDS Development: Revolutionizing Preclinical Predictive Power
Biophysics Reviews | AIP Publishing USA Overview While nanoparticle-based drug delivery systems (DDS) have advanced significantly, their preclinical evaluation's predictive power has been a bottleneck. The integration of nanoparticles wi... -
Antibiotics Reshape Gut Microbiome, Doubling Circulation Time and Tumor Accumulation of Nano-Chemotherapy, Improving Survival
University of Texas M. D. Anderson Cancer Center USA Overview Researchers at The University of Texas MD Anderson Cancer Center discovered that reshaping the gut microbiome with a short course of antibiotics can enhance the delivery of na...
12